Manufacturing facilities for the G47Δ oncolytic virus product
First written in FY2017. 2 of 6 entries say "Advanced", first in FY2021. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「In the new business area, we are working to improve the supply system for the G47Δ oncolytic virus through a review of the manufacturing process.」
Continuing to review the manufacturing process for the G47Δ product to improve the supply system. - FY2025G47Δ product supply shortage and manufacturing process reviewAnnual report
「Supply of the G47Δ oncolytic virus product for cancer treatment has remained below the initial plan. We are currently reviewing the manufacturing process with the aim of delivering the product to medical institutions and patients who wish to use it.」
Supply of G47Δ is below the initial plan, and the manufacturing process is being reviewed to improve supply. - FY2023AdvancedAnnual report
「We decided to make a strategic investment of approximately ¥12 billion in the Gosen Plant and Niigata Factory to strengthen the business foundation for the G47Δ oncolytic virus product for cancer treatment and increase supply capacity with a view to the future.」
Decided to make a strategic investment of approximately ¥12 billion in the G47Δ product to increase supply capacity and strengthen the business foundation. - FY2021AdvancedAnnual report
「At the Gosen Plant, development of a mass-production method for the commercialization of the viral product G47Δ (Delta) for cancer treatment progressed, and at the end of last year, DAIICHI SANKYO COMPANY,LIMITED, the marketing authorization holder, filed an application for marketing approval. The application is currently under review by the Pharmaceuticals and Medical Devices Agency (PMDA), and because the product has been designated under the SAKIGAKE designation system, early approval is expected.」
Following completion of the G47Δ manufacturing facilities, development of a mass-production method continued, and the product has advanced to the application and review stage for marketing approval. - FY2019AchievedAnnual report
「At デンカ生研株式会社, manufacturing facilities for the viral product G47Δ (Delta) have been completed, and development of a mass-production method is progressing toward commercialization.」
The manufacturing facilities for G47Δ have been completed. Meanwhile, development of a mass-production method toward commercialization is continuing. - FY2017First statedAnnual report
「This includes the construction of manufacturing facilities for the G47Δ oncolytic virus product at デンカ生研株式会社.」
Advancing development of a mass-production method and construction of manufacturing facilities for the commercialization of G47Δ, with the aim of developing the new field of oncolytic virus therapy.